Nieto-Flores J, Villafán-Bernal JR, Rivera-León EA, Llamas-Covarrubias IM, González-Hita ME, Alcalá-Zermeno JL, Sánchez-Enríquez S

Language: Spanish
References: 34
Page: 185-189
PDF size: 174.73 Kb.

ABSTRACT

Introduction: Osteocalcin has been shown to have an inverse relationship with blood glucose, insulin resistance and adiposity. Objective: To determine osteocalcin normal serum concentration in Mexican healthy adults and compare it with values reported in other populations. Method: Carboxylated and undercarboxylated osteocalcin serum concentrations were determined in 100 healthy adults by means of enzyme immunoassay; osteocalcin total concentration was calculated. A descriptive comparison was made with other populations’ values reported in the literature. Results: Carboxylated and undercarboxylated osteocalcin median concentrations were 3.22 ng/mL and 1.61 ng/mL, respectively. Mean total osteocalcin was 7.40 ± 5.11 ng/mL. There was no significant difference between the osteocalcin values in our population and those of populations where similar quantification methods to ours were used. Conclusion: Osteocalcin total serum concentration mean in the analyzed population was 7.40 ng/mL. There are subtle variations between populations that are attributable to genetic and population factors; however, the quantification method was the only variable that was shown to significantly influence on osteocalcin levels in healthy populations.

REFERENCES

1. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007:130(3):456-469.

2. Li J, Zhang H, Yang C, Li Y, Dai Z. An overview of osteocalcin progress. J Bone Miner Metab. 2016;34(4):367-379.

3. Chapurlat RD, Confavreux CB. Novel biological markers of bone: from bone metabolism to bone physiology. Rheumatology (Oxford). 2016 ;55 (10):1714-1725.

4. Oury F, Khrimian L, Denny CA, Gardin A, Chamouni A, Goeden N, et al. Maternal and offspring pools of osteocalcin influence brain development and functions. Cell. 2013:155(1):228-241.

5. Power MJ, Fottrell PF. Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci. 1991:28(4):287-335.

6. Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int.2009:20(6):843-851.

7. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2005:26(4):97-122.

8. Seibel MJ. Biochemical markers of bone turnover: Part II: Clinical applications in the management of osteoporosis. Clin Biochem Rev. 2006:27(3):123-138

9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003:289(19):2560-2572.

10. Organización Mundial de la Salud. Dieta, nutrición y prevención de enfermedades crónicas. Serie de Informes Técnicos Núm. 797. Ginebra, Suiza: OMS: 1990.

11. National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 01-3670. Bethesda, Md: National Institutes of Health; 2001.

12. Price PA, Lothringer JW, Nishimoto SK. Absence of the vitamin K-dependent bone protein in fetal rat mineral. Evidence for another gamma- carboxyglutamic acid-containing component in bone. J Biol Chem. 1980:255(7):2938-2942.

13. Koyama N, Ohara K, Yokota H, Kurome T, Katayama M, Hino F, et al. A one step sandwich enzyme immunoassay for γ-carboxylated osteocalcin using monoclonal antibodies. J Immunol. Methods. 1991;139(1):17-23.

14. Garnero P, Grimaux M, Demiaux B, Preaudat C, Seguin P, Delmas PD. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res. 1992;7(12):1389-1398.

15. Vergnaud P, Garnero P, Meunier PJ, Bréart G, Kamihagi K, Delmas PD. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab. 1997:82(3):719-724.

16. Pietschmann P, Schernthaner G, Woloszczuk W. Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications. Diabetologia. 1988:31(12):892-895.

17. Akin O, Göl K, Aktürk M, Erkaya S. Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements. Gynecol Endocrinol. 2003:17(1):19-29.

18. Rosato MT, Schneider SH, Shapses SA. Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin- dependent diabetes mellitus. Calcif Tissue Int. 1998:63(2):107-111.

19. Achemlal L, Tellal S, Rkiouak F, Nouijai A, Bezza A, Ghafir D, et al. Bone metabolism in male patients with type 2 diabetes. Clin Rheumatol. 2005:24(5):493-496.

20. Dobnig H, Piswanger-Sölkner JC, Roth M, Obermayer-Pietsch B, Tiran A, Strele A, et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab. 2006:91(9):3355-3363.

21. Cutrim DM, Pereira FA, De-Paula FJ, Foss MC. Lack of relationship between glycemic control and bone mineral density in type 2 diabetes mellitus. Braz J Med Biol Res. 2007:40(2):221-227.

22. Shankar S, Hosking DJ. Biochemical assessment of Paget’s disease of bone. J Bone Miner Res. 2006:21(Suppl 2):P22-P27.

23. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008;34(7):629-639.

24. Magni P, Macchi C, Sirtori CR, Corsi-Romanelli MM. Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases. Clin Chem Lab Med. 2016;54(10):1579-1587.

25. Villafán-Bernal JR, Llamas-Covarrubias MA, Muñoz-Valle JF, Rivera- León EA, González-Hita ME, Bastidas-Ramírez BE, et al. A cut-point value of uncarboxylated to carboxylated index is associated with glycemic status markers in type 2 diabetes. J Investig Med. 2014:62(1):33-36.

26. Kelly PJ, Hopper JL, Macaskill GT, Pocock NA, Sambrook PN, Eisman JA. Genetic factors in bone turnover. J Clin Endocrinol Metab. 1991:72(4):808-813.

27. Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev. 1989:69(3):990-1047

28. O’Connor E, Molgaard C, Michaelsen KF, Jakobsen J, Cashman KD. Vitamin D-vitamin K interaction: effect of vitamin D supplementation on serum percentage undercarboxylated osteocalcin, a sensitive measure of vitamin K status, in Danish girls.Br J Nutr. 2010;104(8):1091-1095.

29. Stroud ML, Stilgoe S, Stott VE, Alhabian O, Salman K. Vitamin D-A review. Aust Fam Physician. 2008:37(12):1002-1005.

30. Giton F, Caron P, Bérubé R, Bélanger A, Barbier O, Fiet J. Plasma estrone sulfate assay in men: Comparison of radioimmunoassay, mass spectrometry coupled to gas chromatography (GC-MS), and liquid chromatography- tandem mass spectrometry (LC-MS/MS). Clin Chim Acta. 2010;411(17-18):1208-1213.

31. Leguin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem. 2005;51(12):2415-2418.

32. Carrozza C, Corsello SM, Paragliola RM, Ingraudo F, Palumbo S, Locantore P, et al. Clinical accuracy of midnight salivary cortisol measured by automated electrochemiluminescence immunoassay method in Cushing’s syndrome. Ann Clin Biochem. 2010;47(Pt 3):228-232.

33. Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann Clin Biochem. 2000;37(Pt 4):432-446.

34. Levinger JD, Zajac EG. Osteocalcin, undercarboxylated osteocalcin, and glycemic control in human subjects. En: Karsenty G. Translational endocrinology of bone. EE. UU.: Elsevier; 2013.